Polaryx Therapeutics (PLYX) Corporate presentation summary

Strategic focus and market opportunity

• Dedicated to rare pediatric lysosomal storage disorders (LSDs) with disease-modifying drug candidates targeting highly unmet orphan indications.

• Aims to establish standard of care across the LSD market, unlocking multi-billion-dollar opportunities.

• Multiple regulatory designations and expedited pathways support commercialization strategy.

• Proprietary oral formulations and robust IP protection enhance patient adoption and market share.

• Addressable market estimated at 50,000 LSD patients across US, EU, and select global regions.

Pipeline and clinical development

• Lead candidate PLX-200 is an oral small molecule activating PPARα, promoting lysosome biogenesis and anti-inflammatory gene expression.

• IND-approved Phase 2 SOTERIA basket trial covers CLN2, CLN3, Krabbe, and Sandhoff diseases, with pivotal trials cleared for CLN2 and CLN3.

• Additional pipeline includes PLX-300 (antioxidant/anti-inflammatory), PLX-100 (combination therapy), and PLX-400 (gene therapy).

• SOTERIA trial design allows for flexible inclusion of new indications as more data emerges.

• Adaptive trial design leverages natural history data for expedited approval in case of compelling results.

Preclinical and proof-of-concept data

• PLX-200 demonstrated efficacy in animal models of CLN2, CLN3, Krabbe, and Sandhoff, improving survival, reducing substrate accumulation, and enhancing motor function.

• Multiple modes of action address key disease mechanisms, including lysosomal biogenesis, anti-inflammation, and neuronal protection.

• Preclinical data supports the potential for broad therapeutic value across LSDs.